Highlights RenovoRx, Inc.

Equities

RNXT

US75989R1077

Market Closed - Nasdaq Other stock markets 21:30:00 25/06/2024 BST			5-day change	1st Jan Change
1.13 ^USD	-1.31%		-17.52%	-50.66%

06-10	RenovoRx, Inc. Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships	CI
05-21	RenovoRx, Inc. Announces Publication of Results of Pre-Clinical Studies Support Efficacy and Drug Delivery Mechanism Potential	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

RenovoRx, Inc. Announces Publication of Results of Pre-Clinical Studies Support Efficacy and Drug Delivery Mechanism Potential	05-21	CI
RenovoRx, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-10	CI
RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting	04-16	CI
RenovoRx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-01	CI
Renovorx Engages Oklahoma University Health as First Clinical Site in Preparation for the Pivotal Phase Iiiougar Clinical Trial in Bile Duct Cancer	12-21	CI
RenovoRx, Inc. Files New International Patent for Novel Targeted Combination Drug-Delivery Oncology Therapy Platform	12-13	CI
RenovoRx, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
RenovoRx, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	16/08/23	CI
Renovorx and Imugene Announces Researchcollaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion Platform	20/07/23	CI
RenovoRx, Inc Announces New Positive Interim Phase III Data Demonstrating RenovoGem(TM) Delays Cancer Progression by Eight Months in Locally Advanced Pancreatic Cancer	29/06/23	CI
Renovorx, Inc. Initiates Patient Enrollment At University of Texas Southwestern Medical Center for Pivotal Phase III Tiger-Pac Clinical Trial	01/06/23	CI
RenovoRx, Inc. Announces Late-Breaking Oral Presentation at 2023 ESMO World Congress on Gastrointestinal Cancer	25/05/23	CI
RenovoRx, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/05/23	CI
RenovoRx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	02/03/23	CI
Renovorx, Inc. Announces Initial Results from A Pharmacokinetic (PK) Substudy Within the Phase III Un-Blinded Randomized Control Tiger-Pac Clinical Trial	18/01/23	CI
RenovoRx, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22	CI
RenovoRx, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	12/08/22	CI
Renovorx Launches "The Renovorx Story" Video Series	13/07/22	CI
RenovoRx, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	13/05/22	CI
RenovoRx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	30/03/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights RenovoRx, Inc.

Equities

RNXT

US75989R1077

Highlights

Filters